Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1983 Mar;47(3):367–372. doi: 10.1038/bjc.1983.55

Decreased blood histamine levels in patients with solid malignant tumours.

C Burtin, C Noirot, J Paupe, P Scheinmann
PMCID: PMC2011313  PMID: 6830687

Abstract

In a one-year follow-up study, 444 blood histamine determinations were performed in 163 patients with solid malignant tumours. Compared with normal subjects, blood histamine levels were significantly lower in patients with unresected primary tumours (30.7 +/- 19.9 ng ml-1), metastases (34.1 +/- 17.1 ng ml-1), or both (24.5 +/- 12.8 ng ml-1). By contrast, after successful tumour resection, histamine blood levels were nearly normal (52.1 +/- 18.4 ng ml-1, versus 59.6 +/- 22.6 in control patients). Stability of the histamine blood levels was associated with stability of the disease. A progressive decrease in histamine blood levels preceded clinical relapse or detection of metastasis. In patients with consecutive histamine blood levels which were less than 15 ng ml-1, survival did not exceed 2 months. In patients with gastrointestinal tumours, blood histamine levels provided information additional to that derived from serum CEA determination. In patients with non-gastrointestinal tumours, the blood histamine level may be of more value than CEA as a marker of disease progression.

Full text

PDF
367

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alderson M. Mortality from malignant disease in patients with asthma. Lancet. 1974 Dec 21;2(7895):1475–1477. doi: 10.1016/s0140-6736(74)90217-7. [DOI] [PubMed] [Google Scholar]
  2. Allegra J., Lipton A., Harvey H., Luderer J., Brenner D., Mortel R., Demers L., Gillin M., White D., Trautlein J. Decreased prevalence of immediate hypersensitivity (atopy) in a cancer population. Cancer Res. 1976 Sep;36(9 PT1):3225–3226. [PubMed] [Google Scholar]
  3. Asboe-Hansen G. Mast cells in health and disease. Bull N Y Acad Med. 1968 Aug;44(8):1048–1056. [PMC free article] [PubMed] [Google Scholar]
  4. Augustin R., Chandradasa K. D. IgE levels and allergic skin reactions in cancer and non-cancer patients. Int Arch Allergy Appl Immunol. 1971;41(1):141–143. doi: 10.1159/000230505. [DOI] [PubMed] [Google Scholar]
  5. Blöndal T., Nõu E. Circulating IgE levels in patients with bronchial carcinoma. Br J Dis Chest. 1981 Jan;75(1):77–80. doi: 10.1016/s0007-0971(81)80010-1. [DOI] [PubMed] [Google Scholar]
  6. Burtin C., Scheinmann P., Salomon J. C., Lespinats G., Canu P. Decrease in tumour growth by injections of histamine or serotonin in fibrosarcoma-bearing mice: influence of H1 and H2 histamine receptors. Br J Cancer. 1982 Jan;45(1):54–60. doi: 10.1038/bjc.1982.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Burtin C., Scheinmann P., Salomon J. C., Lespinats G., Loisillier F., Canu P. The influence of intraperitoneal injections of histamine on tumour growth in fibrosarcoma-bearing mice. Cancer Lett. 1981 Apr;12(3):195–201. doi: 10.1016/0304-3835(81)90068-9. [DOI] [PubMed] [Google Scholar]
  8. Dvorak A. M., Galli S. J., Galli A. S., Hammond M. E., Churchill W. H., Jr, Dvorak H. F. Tumor-basophil interactions in vitro--a scanning and transmission electron microscopic study. J Immunol. 1979 Jun;122(6):2447–2457. [PubMed] [Google Scholar]
  9. FISHERMAN E. W. Does the allergic diathesis influence malignancy? J Allergy. 1960 Jan-Feb;31:74–78. doi: 10.1016/0021-8707(60)90026-5. [DOI] [PubMed] [Google Scholar]
  10. Farram E., Nelson D. S. Mouse mast cells as anti-tumor effector cells. Cell Immunol. 1980 Oct;55(2):294–301. doi: 10.1016/0008-8749(80)90162-8. [DOI] [PubMed] [Google Scholar]
  11. Ford R. M. Primary lung cancer and asthma. Ann Allergy. 1978 Apr;40(4):240–242. [PubMed] [Google Scholar]
  12. Hartveit F. Mast cells and metachromasia in human breast cancer: their occurrence, significance and consequence: a preliminary report. J Pathol. 1981 May;134(1):7–11. doi: 10.1002/path.1711340103. [DOI] [PubMed] [Google Scholar]
  13. Hughes W. F., Raitz R. L. A comparison of cancer occurrence in allergic and nonallergic populations. Ann Allergy. 1979 Sep;43(3):163–164. [PubMed] [Google Scholar]
  14. Hällgren R., Arrendal H., Hiesche K., Lundquist G., Nöu E., Zetterström O. Elevated serum immunoglobulin E in bronchial carcinoma: its relation to the histology and prognosis of the cancer. J Allergy Clin Immunol. 1981 May;67(5):398–406. doi: 10.1016/0091-6749(81)90086-5. [DOI] [PubMed] [Google Scholar]
  15. Jacobs D., Landon J., Houri M., Merrett T. G. Circulating levels of immunoglobulin E in patients with cancer. Lancet. 1972 Nov 18;2(7786):1059–1061. doi: 10.1016/s0140-6736(72)92341-0. [DOI] [PubMed] [Google Scholar]
  16. LOGAN J., SAKER D. The incidence of allergic disorders in cancer. N Z Med J. 1953 Jun;52(289):210–212. [PubMed] [Google Scholar]
  17. Lynch N. R., Salomon J. C. Tumour-associated inhibition of immediate hypersensitivity reactions in mice. Immunology. 1977 May;32(5):645–650. [PMC free article] [PubMed] [Google Scholar]
  18. Mackay W. D. The incidence of allergic disorders and cancer. Br J Cancer. 1966 Sep;20(3):434–437. doi: 10.1038/bjc.1966.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mahapatro R. C., Bowers H. M., Jr Distribution of mast cells in the axillary lymph nodes of breast cancer patients. Cancer. 1979 Aug;44(2):592–597. doi: 10.1002/1097-0142(197908)44:2<592::aid-cncr2820440228>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  20. McKee W. D., Arnold C. A., Perlman M. D. A double-blind study of the comparative incidence of malignancy and allergy. J Allergy. 1967 May;39(5):294–301. doi: 10.1016/0021-8707(67)90093-7. [DOI] [PubMed] [Google Scholar]
  21. Meers P. D. Allergy and cancer. Lancet. 1973 Apr 21;1(7808):884–885. doi: 10.1016/s0140-6736(73)91452-9. [DOI] [PubMed] [Google Scholar]
  22. Pauwels R., Van der Straeten M. Letter: Circulating IgE levels in patients with cancer. Lancet. 1975 Mar 8;1(7906):582–582. doi: 10.1016/s0140-6736(75)91610-4. [DOI] [PubMed] [Google Scholar]
  23. SHORE P. A., BURKHALTER A., COHN V. H., Jr A method for the fluorometric assay of histamine in tissues. J Pharmacol Exp Ther. 1959 Nov;127:182–186. [PubMed] [Google Scholar]
  24. Saavedra-Delgado A. M., Mathews K. P., Pan P. M., Kay D. R., Muilenberg M. L. Dose-response studies of the suppression of whole blood histamine and basophil counts by prednisone. J Allergy Clin Immunol. 1980 Dec;66(6):464–471. doi: 10.1016/0091-6749(80)90007-x. [DOI] [PubMed] [Google Scholar]
  25. Scheinmann P., Lebel B., Lynch N. R., Salomon J. C., Paupe J. R., Burtin C. Histamine levels in blood and other tissues of male and female C3H mice. II. Mice carrying a 3-methyl-cholanthrene-induced tumor [proceedings]. Agents Actions. 1979 Apr;9(1):95–96. doi: 10.1007/BF02024138. [DOI] [PubMed] [Google Scholar]
  26. Simu G., Csaba G. Mast cells in tumour-bearing patients. Acta Morphol Acad Sci Hung. 1972;20(3):327–338. [PubMed] [Google Scholar]
  27. Siraganian R. P., Brodsky M. J. Automated histamine analysis for in vitro allergy testing. I. A method utilizing allergen-induced histamine release from whole blood. J Allergy Clin Immunol. 1976 Jun;57(6):525–540. doi: 10.1016/0091-6749(76)90003-8. [DOI] [PubMed] [Google Scholar]
  28. Ure D. M. Negative assoication between allergy and cancer. Scott Med J. 1969 Feb;14(2):51–54. doi: 10.1177/003693306901400203. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES